Lunger John
Insider CIK 1784487 · GNCA Director · ADAP Chief Patient Supply Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2025-02-20 | 2025-02-20 | 1,074,696 | — | $0 | 1,074,696 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2025-02-20 | 2025-02-20 | 1,612,032 | — | $0 | 1,612,032 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2025-01-17 | 2025-01-17 | 5,584 | $0.58 | $3.2K | 7,510 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2025-01-15 | 2025-01-15 | 9,803 | $0.57 | $5.6K | 13,756 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2025-01-13 | 2025-01-15 | 4,268 | $0.59 | $2.5K | 5,845 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2025-01-13 | 2025-01-15 | 5,471 | $0.59 | $3.2K | 7,623 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2024-01-17 | 2024-01-17 | 12,805 | $0.67 | $8.6K | 19,015 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2024-01-17 | 2024-01-17 | 5,309 | $0.67 | $3.6K | 7,785 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2024-01-16 | 2024-01-17 | 4,681 | $0.79 | $3.7K | 7,023 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2024-01-15 | 2024-01-17 | 2,544,432 | — | $0 | 2,544,432 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2024-01-15 | 2024-01-17 | 565,416 | — | $0 | 565,416 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2024-01-12 | 2024-01-12 | 5,220 | $0.85 | $4.4K | 7,874 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2024-01-11 | 2024-01-12 | 4,009 | $0.84 | $3.4K | 6,104 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2023-08-01 | 2023-08-01 | 3,096 | $0.91 | $2.8K | 4,718 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2023-01-17 | 2023-01-17 | 190,920 | — | $0 | 190,920 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2023-01-17 | 2023-01-17 | 314,256 | — | $0 | 314,256 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2023-01-17 | 2023-01-17 | 1,407,072 | — | $0 | 1,407,072 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2023-01-17 | 2023-01-17 | 4,440 | $1.86 | $8.3K | 7,264 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2023-01-12 | 2023-01-12 | 4,973 | $1.71 | $8.5K | 8,121 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2023-01-11 | 2023-01-12 | 3,843 | $1.75 | $6.7K | 6,270 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2023-01-04 | 2023-01-04 | 1,100 | $1.69 | $1.9K | 1,725 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2022-08-01 | 2022-08-01 | 2,983 | $1.77 | $5.3K | 4,829 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2022-07-05 | 2022-07-05 | 1,973 | $1.68 | $3.3K | 3,104 | SEC↗ |
| GNCA GENOCEA BIOSCIENCES, INC. | A Award deriv | 2022-03-03 | 2022-03-07 | 30,000 | — | $0 | 30,000 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2022-01-18 | 2022-01-18 | 4,368 | $3.19 | $13.9K | 7,336 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2022-01-12 | 2022-01-13 | 1,407,072 | — | $0 | 1,407,072 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2022-01-12 | 2022-01-13 | 314,256 | — | $0 | 314,256 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2022-01-12 | 2022-01-13 | 1,076 | $3.54 | $3.8K | 1,749 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2022-01-11 | 2022-01-13 | 3,770 | $3.56 | $13.4K | 6,343 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2022-01-04 | 2022-01-05 | 1,070 | $4.06 | $4.3K | 1,755 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2021-08-02 | 2021-08-02 | 2,939 | $3.58 | $10.5K | 4,873 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2021-07-02 | 2021-07-02 | 1,907 | $4.26 | $8.1K | 3,170 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2021-01-19 | 2021-01-19 | 4,358 | $5.67 | $24.7K | 7,346 | SEC↗ |
| ADAP | S Sale | 2021-01-12 | 2021-01-12 | 1,058 | $6.15 | $6.5K | 1,767 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2021-01-11 | 2021-01-11 | 242,712 | — | $0 | 242,712 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2021-01-11 | 2021-01-11 | 1,086,816 | — | $0 | 1,086,816 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2021-01-04 | 2021-01-05 | 1,065 | $5.33 | $5.7K | 1,760 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2020-08-03 | 2020-08-04 | 4,823 | $9.25 | $44.6K | 8,066 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2020-01-16 | 2020-01-17 | 1,257,744 | — | $0 | 1,257,744 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2020-01-16 | 2020-01-17 | 280,896 | — | $0 | 280,896 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2020-01-14 | 2020-01-15 | 1,144 | $5.13 | $5.9K | 1,681 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2020-01-06 | 2020-01-07 | 1,148 | $1.20 | $1.4K | 1,677 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2019-08-01 | 2019-08-05 | 839,568 | — | $0 | 839,568 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2019-08-01 | 2019-08-05 | 187,500 | — | $0 | 187,500 | SEC↗ |